Breaking News Instant updates and real-time market news.

CPRI

Capri Holdings

$8.53 /

+0.4 (+4.92%)

09:28
04/06/20
04/06
09:28
04/06/20
09:28

Capri Holdings to furlough all 7,000 North America retail store employees

Capri Holdings provided an update on the coordinated actions the company is taking to protect our employees and maintain the company's financial position in response to the continued global health and economic impact of the COVID-19 pandemic. As of April 1, the company had total cash and cash equivalents on its balance sheet of approximately $900M. The company has fully drawn the remaining $300M of availability under its revolving credit facility. For FY21, the company's board of directors annual total cash compensation will be reduced by 50%. John Idol, chairman and CEO, Michael Kors, chief creative officer of Michael Kors, Donatella Versace, chief creative officer of Versace and Sandra Choi, chief creative officer of Jimmy Choo, have each voluntarily elected to forgo their salary for FY21. In addition, the company will be exploring opportunities to reduce overall salaries at various levels throughout the organization by approximately 20%. In the future the company anticipates reducing its corporate workforce in order to generate additional payroll savings. Since March 18, the company has provided salary continuation and benefits to all retail store employees impacted by its temporary store closures that started on that same date and were expected to end on April 10. The company now anticipates that retail stores in North America and Europe will be closed until approximately June 1 and will only reopen once it is deemed safe to do so. The company has therefore made the decision that effective April 11, it will furlough all of its approximately 7,000 North America retail store employees. During this time, the company will continue to pay the employer portion of benefits to support impacted retail personnel. In the United States and Canada, furloughed employees are also eligible for unemployment insurance as well as other government relief programs where available. The company expects to require a smaller workforce as it resets its business post-COVID-19. The goal of the company is to return as many retail employees as possible to work in the second half of the fiscal year as its business rebuilds. The company is applying for national payroll subsidy programs in various countries throughout Europe to further reduce payroll expense. The company is diligently managing inventory purchases in light of the store closures in North America and EMEA and the anticipated decreased demand in the second half of the fiscal year by reducing or canceling commitments, redeploying inventory and consolidating upcoming seasons. The company is working closely with its partners to extend the terms of its future payables. Additionally, the company is working to secure relief of certain payables in order to maintain its financial flexibility for the long term. The company is eliminating all non-essential operating expenses, including decreasing marketing spend, delaying or canceling select new store openings, reducing external third-party services and halting unnecessary systems implementations in order to reduce costs. The company is suspending the remaining $400M under its current share repurchase program.

  • 08

    Apr

CPRI Capri Holdings
$8.53 /

+0.4 (+4.92%)

03/30/20 Wells Fargo
Capri Holdings downgraded to Equal Weight from Overweight at Wells Fargo
03/19/20 Morgan Stanley
Morgan Stanley lowers targets for Gap, Macy's, and four other levered retailers
03/13/20 Deutsche Bank
Capri Holdings downgraded to Hold from Buy at Deutsche Bank
02/03/20 BMO Capital
Capri Holdings initiated with an Outperform at BMO Capital

TODAY'S FREE FLY STORIES

Syndicate
Caladrius announces $4.3M registered direct offering priced at-the-market » 08:24
05/26/20
05/26
08:24
05/26/20
08:24
CLBS

Caladrius

$2.08 /

+0.16 (+8.33%)

Caladrius Biosciences…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
CLBS Caladrius
$2.08 /

+0.16 (+8.33%)

CLBS Caladrius
$2.08 /

+0.16 (+8.33%)

05/22/20 Brookline
Caladrius initiated with a Buy at Brookline
05/18/20 Dawson James
Caladrius downgraded to Neutral from Buy at Dawson James
CLBS Caladrius
$2.08 /

+0.16 (+8.33%)

Recommendations
Sanofi overhang removed, Regeneron capital structure improving, says SVB Leerink » 08:24
05/26/20
05/26
08:24
05/26/20
08:24
REGN

Regeneron

$569.94 /

+8.55 (+1.52%)

, SNY

Sanofi

$47.31 /

-0.18 (-0.38%)

SVB Leerink analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
REGN Regeneron
$569.94 /

+8.55 (+1.52%)

SNY Sanofi
$47.31 /

-0.18 (-0.38%)

REGN Regeneron
$569.94 /

+8.55 (+1.52%)

06:29 Today Wells Fargo
Regeneron upgraded to Overweight at Wells Fargo on EYLEA Survey
04:44 Today Wells Fargo
Regeneron upgraded to Overweight from Equal Weight at Wells Fargo
05/19/20 Roth Capital
Rapt CCR4 antagonist may be competitive against Dupixent, says Roth Capital
05/15/20 Piper Sandler
Ocular Therapeutix early OTX-TKI data encouraging, says Piper Sandler
SNY Sanofi
$47.31 /

-0.18 (-0.38%)

05/12/20 Oppenheimer
Novavax price target raised to $38.50 from $19 at Oppenheimer
05/06/20 Oppenheimer
Regeneron price target raised to $625 from $525 at Oppenheimer
04/30/20 Roth Capital
aTyr Pharma '1923 another 'shot on goal' in COVID-19 fight, says Roth Capital
04/28/20 Barclays
Sanofi price target raised to EUR 85 from EUR 80 at Barclays
REGN Regeneron
$569.94 /

+8.55 (+1.52%)

SNY Sanofi
$47.31 /

-0.18 (-0.38%)

REGN Regeneron
$569.94 /

+8.55 (+1.52%)

SNY Sanofi
$47.31 /

-0.18 (-0.38%)

REGN Regeneron
$569.94 /

+8.55 (+1.52%)

SNY Sanofi
$47.31 /

-0.18 (-0.38%)

REGN Regeneron
$569.94 /

+8.55 (+1.52%)

SNY Sanofi
$47.31 /

-0.18 (-0.38%)

Hot Stocks
Driver sends letter to First United Corp shareholders » 08:23
05/26/20
05/26
08:23
05/26/20
08:23
FUNC

First United Corp

$13.75 /

-0.31 (-2.20%)

Driver, one of the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
FUNC First United Corp
$13.75 /

-0.31 (-2.20%)

Syndicate
Outlook Therapeutics announces $16M private placement for ONS-5010 development » 08:23
05/26/20
05/26
08:23
05/26/20
08:23
OTLK

Outlook Therapeutics

$0.74 /

+0.009 (+1.24%)

Outlook Therapeutics…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
OTLK Outlook Therapeutics
$0.74 /

+0.009 (+1.24%)

OTLK Outlook Therapeutics
$0.74 /

+0.009 (+1.24%)

05/05/20 Brookline
Outlook Therapeutics initiated with a Buy at Brookline
04/14/20 H.C. Wainwright
Outlook's NORSE-1 remaining on track 'comes as a relief,' says H.C. Wainwright
09/11/19 Ladenburg
Outlook Therapeutics initiated with a Buy at Ladenburg
07/18/19 H.C. Wainwright
Outlook Therapeutics initiated with a Buy at H.C. Wainwright
OTLK Outlook Therapeutics
$0.74 /

+0.009 (+1.24%)

Upgrade
Linde plc upgraded to Buy from Hold at Argus » 08:22
05/26/20
05/26
08:22
05/26/20
08:22
LIN

Linde plc

$190.98 /

-2.615 (-1.35%)

Argus analyst Bill…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
LIN Linde plc
$190.98 /

-2.615 (-1.35%)

LIN Linde plc
$190.98 /

-2.615 (-1.35%)

05/18/20 UBS
Linde plc price target raised to EUR 200 from EUR 190 at UBS
05/06/20 Berenberg
Linde plc price target lowered to EUR 215 from EUR 225 at Berenberg
04/15/20
Fly Intel: Top five analyst upgrades
04/15/20 Bernstein
Linde plc upgraded to Market Perform from Underperform at Bernstein
LIN Linde plc
$190.98 /

-2.615 (-1.35%)

LIN Linde plc
$190.98 /

-2.615 (-1.35%)

LIN Linde plc
$190.98 /

-2.615 (-1.35%)

LIN Linde plc
$190.98 /

-2.615 (-1.35%)

Recommendations
Ciena has 'at least a one-year lead' with Waveserver 5, says Jefferies » 08:22
05/26/20
05/26
08:22
05/26/20
08:22
CIEN

Ciena

$52.81 /

+1.05 (+2.03%)

Jefferies analyst George…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CIEN Ciena
$52.81 /

+1.05 (+2.03%)

CIEN Ciena
$52.81 /

+1.05 (+2.03%)

05/22/20 MKM Partners
Ciena price target raised to $62 from $54 at MKM Partners
05/13/20 B. Riley FBR
Ciena downgraded to Neutral on marco uncertainty at B. Riley FBR
05/13/20 B. Riley FBR
Ciena downgraded to Neutral from Buy at B. Riley FBR
04/16/20 Morgan Stanley
Ciena downgraded to Equal Weight on installation challenges at Morgan Stanley
CIEN Ciena
$52.81 /

+1.05 (+2.03%)

CIEN Ciena
$52.81 /

+1.05 (+2.03%)

CIEN Ciena
$52.81 /

+1.05 (+2.03%)

CIEN Ciena
$52.81 /

+1.05 (+2.03%)

Hot Stocks
Edison Nation acquires 50% interest in Global Clean Solutions » 08:20
05/26/20
05/26
08:20
05/26/20
08:20
EDNT

Edison Nation

$2.34 /

+0.06 (+2.63%)

Edison Nation is pleased…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
EDNT Edison Nation
$2.34 /

+0.06 (+2.63%)

Hot Stocks
GTT Communications promotes Ernie Ortega to chief revenue officer » 08:19
05/26/20
05/26
08:19
05/26/20
08:19
GTT

GTT Communications

$9.03 /

-0.02 (-0.22%)

GTT announced that Ernie…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
GTT GTT Communications
$9.03 /

-0.02 (-0.22%)

GTT GTT Communications
$9.03 /

-0.02 (-0.22%)

05/11/20 SunTrust
GTT Communications downgraded to Hold from Buy at SunTrust
05/11/20 SunTrust
GTT Communications downgraded to Hold from Buy at SunTrust
04/17/20 Oppenheimer
GTT Communications downgraded to Perform from Outperform at Oppenheimer
04/17/20 Oppenheimer
GTT Communications downgraded to Perform from Outperform at Oppenheimer
GTT GTT Communications
$9.03 /

-0.02 (-0.22%)

GTT GTT Communications
$9.03 /

-0.02 (-0.22%)

GTT GTT Communications
$9.03 /

-0.02 (-0.22%)

Recommendations
Marvell price target raised to $35 from $30 at Susquehanna » 08:19
05/26/20
05/26
08:19
05/26/20
08:19
MRVL

Marvell

$30.13 /

+1.02 (+3.50%)

Susquehanna analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
MRVL Marvell
$30.13 /

+1.02 (+3.50%)

MRVL Marvell
$30.13 /

+1.02 (+3.50%)

05/22/20 B. Riley FBR
Marvell price target raised to $34 from $31 at B. Riley FBR
05/21/20 Cowen
Marvell datapoints indicate softness where they participate, says Cowen
05/21/20 Citi
Marvell price target raised to $35 from $31 at Citi
03/27/20 UBS
UBS upgrades Semiconductor Equipment names, sees supply/demand shock priced in
MRVL Marvell
$30.13 /

+1.02 (+3.50%)

MRVL Marvell
$30.13 /

+1.02 (+3.50%)

MRVL Marvell
$30.13 /

+1.02 (+3.50%)

MRVL Marvell
$30.13 /

+1.02 (+3.50%)

Hot Stocks
Enphase collaborates with University of Washington for 100% renewables grid » 08:18
05/26/20
05/26
08:18
05/26/20
08:18
ENPH

Enphase Energy

$56.32 /

-3.63 (-6.06%)

Enphase Energy announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ENPH Enphase Energy
$56.32 /

-3.63 (-6.06%)

ENPH Enphase Energy
$56.32 /

-3.63 (-6.06%)

05/14/20
Fly Intel: Top five analyst downgrades
05/14/20 Goldman Sachs
Enphase Energy downgraded to Neutral from Buy at Goldman Sachs
05/06/20 Craig-Hallum
Enphase Energy price target raised to $54 from $43 at Craig-Hallum
05/06/20 Barclays
Enphase Energy price target raised to $80 from $76 at Barclays
ENPH Enphase Energy
$56.32 /

-3.63 (-6.06%)

ENPH Enphase Energy
$56.32 /

-3.63 (-6.06%)

ENPH Enphase Energy
$56.32 /

-3.63 (-6.06%)

Hot Stocks
GTT Communications announces departure of CEO » 08:18
05/26/20
05/26
08:18
05/26/20
08:18
GTT

GTT Communications

$9.03 /

-0.02 (-0.22%)

GTT Communications…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
GTT GTT Communications
$9.03 /

-0.02 (-0.22%)

GTT GTT Communications
$9.03 /

-0.02 (-0.22%)

05/11/20 SunTrust
GTT Communications downgraded to Hold from Buy at SunTrust
05/11/20 SunTrust
GTT Communications downgraded to Hold from Buy at SunTrust
04/17/20 Oppenheimer
GTT Communications downgraded to Perform from Outperform at Oppenheimer
04/17/20 Oppenheimer
GTT Communications downgraded to Perform from Outperform at Oppenheimer
GTT GTT Communications
$9.03 /

-0.02 (-0.22%)

GTT GTT Communications
$9.03 /

-0.02 (-0.22%)

GTT GTT Communications
$9.03 /

-0.02 (-0.22%)

Recommendations
ADMA Biologics' use of plasma is 'oldest trick in pandemic playbook', says Maxim » 08:18
05/26/20
05/26
08:18
05/26/20
08:18
ADMA

ADMA Biologics

$2.84 /

-0.065 (-2.24%)

, GILD

Gilead

$73.31 /

-0.17 (-0.23%)

, MRNA

Moderna

$69.00 /

+1.99 (+2.97%)

Maxim analyst Jason…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ADMA ADMA Biologics
$2.84 /

-0.065 (-2.24%)

GILD Gilead
$73.31 /

-0.17 (-0.23%)

MRNA Moderna
$69.00 /

+1.99 (+2.97%)

ADMA ADMA Biologics
$2.84 /

-0.065 (-2.24%)

05/07/20 Oppenheimer
ADMA Biologics price target lowered to $7 from $14 at Oppenheimer
03/16/20 H.C. Wainwright
ADMA Biologics price target lowered to $12 from $14 at H.C. Wainwright
08/12/19 Dawson James
ADMA Biologics downgraded to Neutral from Buy at Dawson James
07/09/19 Jefferies
ADMA Biologics shares 'too cheap' given progress, says Jefferies
GILD Gilead
$73.31 /

-0.17 (-0.23%)

07:02 Today SunTrust
Gilead upgraded to Hold at SunTrust on remdesivir commercial prospects
06:00 Today SunTrust
Gilead upgraded to Hold from Sell at SunTrust
05:02 Today Piper Sandler
Piper Sandler encouraged by remdesivir results published in NEJM
05/21/20 Piper Sandler
Gilead's filgotinib likely being underestimated by Street, says Piper Sandler
MRNA Moderna
$69.00 /

+1.99 (+2.97%)

05/20/20 Morgan Stanley
Moderna price target raised to $90 from $37 at Morgan Stanley
05/19/20 Piper Sandler
Piper trims Moderna target to $100 on capital raise dilution
05/19/20 BMO Capital
Moderna price target raised to $112 from $83 at BMO Capital
05/19/20 H.C. Wainwright
BioNTech upgraded to Buy from Neutral at H.C. Wainwright
ADMA ADMA Biologics
$2.84 /

-0.065 (-2.24%)

GILD Gilead
$73.31 /

-0.17 (-0.23%)

MRNA Moderna
$69.00 /

+1.99 (+2.97%)

GILD Gilead
$73.31 /

-0.17 (-0.23%)

MRNA Moderna
$69.00 /

+1.99 (+2.97%)

GILD Gilead
$73.31 /

-0.17 (-0.23%)

MRNA Moderna
$69.00 /

+1.99 (+2.97%)

GILD Gilead
$73.31 /

-0.17 (-0.23%)

MRNA Moderna
$69.00 /

+1.99 (+2.97%)

Hot Stocks
Materion, Kairos Power form collaboration to develop supply of salt coolant » 08:17
05/26/20
05/26
08:17
05/26/20
08:17
MTRN

Materion

$50.78 /

-1.23 (-2.36%)

Kairos Power and Materion…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
MTRN Materion
$50.78 /

-1.23 (-2.36%)

MTRN Materion
$50.78 /

-1.23 (-2.36%)

04/24/20 KeyBanc
Materion upgraded to Overweight from Sector Weight at KeyBanc
04/24/20 KeyBanc
Materion upgraded to Overweight from Sector Weight at KeyBanc
03/02/20 Sidoti
Materion upgraded to Buy following 25% pullback at Sidoti
03/02/20 Sidoti
Materion upgraded to Buy from Neutral at Sidoti
MTRN Materion
$50.78 /

-1.23 (-2.36%)

Hot Stocks
Citius provides free access to Mino-Lok for healthcare providers » 08:17
05/26/20
05/26
08:17
05/26/20
08:17
CTXR

Citius Pharmaceuticals

$0.92 /

+0.0339 (+3.84%)

Citius Pharmaceuticals…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CTXR Citius Pharmaceuticals
$0.92 /

+0.0339 (+3.84%)

Hot Stocks
Innovation Pharmaceuticals receives data from PHRI on brilacidin » 08:17
05/26/20
05/26
08:17
05/26/20
08:17
IPIX

Innovation Pharmaceuticals

$0.00 /

+ (+0.00%)

Innovation…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
IPIX Innovation Pharmaceuticals
$0.00 /

+ (+0.00%)

Hot Stocks
AnPac Bio announces patent titled 'Apparatus for Improved Disease Detection' » 08:15
05/26/20
05/26
08:15
05/26/20
08:15
ANPC

AnPac Bio

$7.72 /

+ (+0.00%)

AnPac Bio-Medical Science…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ANPC AnPac Bio
$7.72 /

+ (+0.00%)

ANPC AnPac Bio
$7.72 /

+ (+0.00%)

ANPC AnPac Bio
$7.72 /

+ (+0.00%)

Initiation
Jefferies starts Lyra Therapeutics at Buy with $24 price target » 08:14
05/26/20
05/26
08:14
05/26/20
08:14
LYRA

Lyra Therapeutics

$14.53 /

-0.4 (-2.68%)

As previously reported,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
LYRA Lyra Therapeutics
$14.53 /

-0.4 (-2.68%)

06:30 Today BofA
BofA starts Lyra Therapeutics at Buy with $21 price target
06:05 Today BofA
Lyra Therapeutics initiated with a Buy at BofA
05:21 Today Jefferies
Lyra Therapeutics initiated with a Buy at Jefferies
LYRA Lyra Therapeutics
$14.53 /

-0.4 (-2.68%)

Recommendations
Apple checks suggest four new iPhones this year, says Cowen » 08:14
05/26/20
05/26
08:14
05/26/20
08:14
AAPL

Apple

$318.75 /

+1.83 (+0.58%)

Cowen analyst Krish…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AAPL Apple
$318.75 /

+1.83 (+0.58%)

AAPL Apple
$318.75 /

+1.83 (+0.58%)

05/18/20 Wedbush
Apple yet again caught in U.S./China Tensions, says Wedbush
05/12/20 Wedbush
Apple price target raised to $350 from $335 at Wedbush
05/07/20 Bernstein
Google payments to Apple big, predicated on advertising, says Bernstein
05/06/20 Morgan Stanley
Apple's App Store just had strongest month in 2.5 years, says Morgan Stanley
AAPL Apple
$318.75 /

+1.83 (+0.58%)

AAPL Apple
$318.75 /

+1.83 (+0.58%)

AAPL Apple
$318.75 /

+1.83 (+0.58%)

AAPL Apple
$318.75 /

+1.83 (+0.58%)

AAPL Apple
$318.75 /

+1.83 (+0.58%)

Hot Stocks
Turkey bank uses OneSpan's Mobile App Security solution » 08:13
05/26/20
05/26
08:13
05/26/20
08:13
OSPN

OneSpan

$19.45 /

+0.89 (+4.80%)

OneSpan announced that…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
OSPN OneSpan
$19.45 /

+0.89 (+4.80%)

OSPN OneSpan
$19.45 /

+0.89 (+4.80%)

05/19/20
Fly Intel: Top five analyst initiations
05/19/20 Needham
OneSpan initiated with a Buy at Needham
05/18/20 Needham
OneSpan initiated with a Buy at Needham
03/27/20 BTIG
OneSpan assumed with a Neutral at BTIG
OSPN OneSpan
$19.45 /

+0.89 (+4.80%)

OSPN OneSpan
$19.45 /

+0.89 (+4.80%)

Hot Stocks
Privet, UPG send letter to Synalloy stockholders regarding board nominees » 08:12
05/26/20
05/26
08:12
05/26/20
08:12
SYNL

Synalloy

$8.92 /

-0.08 (-0.89%)

Privet and UPG…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SYNL Synalloy
$8.92 /

-0.08 (-0.89%)

Hot Stocks
Anchiano Therapeutics appoints Stan Polovets as chairman of the board » 08:12
05/26/20
05/26
08:12
05/26/20
08:12
ANCN

Anchiano Therapeutics

$1.12 /

+0.03 (+2.75%)

Anchiano Therapeutics…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ANCN Anchiano Therapeutics
$1.12 /

+0.03 (+2.75%)

ANCN Anchiano Therapeutics
$1.12 /

+0.03 (+2.75%)

11/18/19
Fly Intel: Top five analyst downgrades
11/18/19 Baird
Anchiano Therapeutics downgraded to Neutral from Outperform at Baird
11/18/19 Oppenheimer
Anchiano Therapeutics downgraded to Perform from Outperform at Oppenheimer
11/18/19 Ladenburg
Anchiano Therapeutics downgraded to Neutral from Buy at Ladenburg
ANCN Anchiano Therapeutics
$1.12 /

+0.03 (+2.75%)

Hot Stocks
Lightbridge receives Australian patent for nuclear feul assemblies » 08:10
05/26/20
05/26
08:10
05/26/20
08:10
LTBR

Lightbridge

$5.95 /

-0.2 (-3.25%)

Lightbridge Corporation…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
LTBR Lightbridge
$5.95 /

-0.2 (-3.25%)

Hot Stocks
NV5 Global announces $9M in transportation infrastructure awards » 08:10
05/26/20
05/26
08:10
05/26/20
08:10
NVEE

NV5 Global

$43.23 /

-0.78 (-1.77%)

NV5 Global announced that…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
NVEE NV5 Global
$43.23 /

-0.78 (-1.77%)

NVEE NV5 Global
$43.23 /

-0.78 (-1.77%)

05/19/20 Sidoti
NV5 Global initiated with a Buy at Sidoti
05/19/20 Sidoti
NV5 Global initiated with a Buy at Sidoti
04/08/20 Maxim
NV5 Global, ABM Industries, Badger Meter cut to Hold at Maxim
04/08/20 Maxim
NV5 Global downgraded to Hold from Buy at Maxim
NVEE NV5 Global
$43.23 /

-0.78 (-1.77%)

NVEE NV5 Global
$43.23 /

-0.78 (-1.77%)

Recommendations
Cooper Companies price target raised to $325 from $300 at Stephens » 08:09
05/26/20
05/26
08:09
05/26/20
08:09
COO

Cooper Companies

$286.98 /

-0.97 (-0.34%)

Stephens analyst Chris…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
COO Cooper Companies
$286.98 /

-0.97 (-0.34%)

COO Cooper Companies
$286.98 /

-0.97 (-0.34%)

08:08 Today KeyBanc
Cooper Companies price target lowered to $330 from $380 at KeyBanc
05/21/20 Wells Fargo
Cooper Companies price target lowered to $329 from $388 at Wells Fargo
04/21/20 Raymond James
Cooper Companies price target lowered to $340 from $360 at Raymond James
03/16/20 Piper Sandler
Cooper earnings should get boost from rate cut, says Piper Sandler
COO Cooper Companies
$286.98 /

-0.97 (-0.34%)

Downgrade
Texas Capital downgraded to Neutral from Overweight at Piper Sandler » 08:08
05/26/20
05/26
08:08
05/26/20
08:08
TCBI

Texas Capital

$28.54 /

-0.06 (-0.21%)

, IBTX

Independent Bank

$31.27 /

-0.1 (-0.32%)

Piper Sandler analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
TCBI Texas Capital
$28.54 /

-0.06 (-0.21%)

IBTX Independent Bank
$31.27 /

-0.1 (-0.32%)

TCBI Texas Capital
$28.54 /

-0.06 (-0.21%)

03/06/20 SunTrust
SunTrust cuts price targets on Banks amid lower interest rate environment
02/20/20 UBS
Texas Capital upgraded to Neutral from Sell at UBS
01/29/20 Stephens
Stephens ups Independent Bank to Overweight, says integration risk priced in
01/23/20 RBC Capital
Texas Capital price target lowered to $59 from $66 at RBC Capital
IBTX Independent Bank
$31.27 /

-0.1 (-0.32%)

02/20/20 UBS
Texas Capital upgraded to Neutral from Sell at UBS
01/29/20 Stephens
Stephens ups Independent Bank to Overweight, says integration risk priced in
01/29/20 Stephens
Independent Bank upgraded to Overweight from Equal Weight at Stephens
12/18/19 Stephens
Independent Bank downgraded to Equal Weight from Overweight at Stephens
TCBI Texas Capital
$28.54 /

-0.06 (-0.21%)

IBTX Independent Bank
$31.27 /

-0.1 (-0.32%)

IBTX Independent Bank
$31.27 /

-0.1 (-0.32%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.